Latest News & Press Releases

November 15, 2021

Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and Develop Novel SH2 Domain-Targeted Therapies for Cancer and Inflammatory Diseases; Appoints Dr. Nancy Whiting as CEO

–Three SH2 domain inhibitor programs targeting STAT3, STAT6 and an undisclosed non-STAT target are underway –Nancy Whiting, Pharm.D., an industry veteran and one of Fierce Pharma’s Fiercest Women in Life Sciences in 2020, named as chief executive officer –Pedigreed senior leadership team and Series A investors disclosed SAN DIEGO, CA, November 15, 2021 – Recludix […]

Read More »